ArticleInternational journal of nanomedicine2012
Detection of femtomolar level osteosarcoma-related gene via a chronocoulometric DNA biosensor based on nanostructure gold electrode.
Article in International journal of nanomedicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 19 citations in OpenAlex.
- Facile Label-Free Electrochemical DNA Biosensor for Detection of Osteosarcoma-Related Survivin Gene.Biosensors · 2022Article
- MXene Surface on Multiple Junction Triangles for Determining Osteosarcoma Cancer Biomarker by Dielectrode Microgap Sensor.International journal of nanomedicine · 2020Article
- Preparation, Modification, Characterization, and Biosensing Application of Nanoporous Gold Using Electrochemical Techniques.Nanomaterials (Basel, Switzerland) · 2018Review
- Nanostructured gold dsDNA sensor for early detection of breast cancer by beta protein 1 (BPJournal of electroanalytical chemistry (Lausanne, Switzerland) · 2015Article
- Sensitive electrochemical immunosensor based on three-dimensional nanostructure gold electrode.International journal of nanomedicine · 2015Article
- p21 overexpression sensitizes osteosarcoma U2OS cells to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this paper, a sensitive chronocoulometric deoxyribonucleic acid (DNA) biosensor based on a nanostructure gold electrode was fabricated for detection of the femtomolar level survivin gene which was correlated with osteosarcoma by using hexaamine-ruthenium III complexes, [Ru(NH(3))(6)](3+), as the electrochemical indicator. The effect of different frequencies on the real surface area of the nanostructure gold electrode obtained by repetitive square-wave oxidation reduction cycle was investigated. At the optimal frequency of 8000 Hz, the real surface of the developed nanostructure gold electrode was about 42.5 times compared with that of the bare planar gold electrode. The capture probe DNA was immobilized on the nanostructure gold electrode and hybridized with target DNA. Electrochemical signals of hexaamine-ruthenium III bound to the anionic phosphate of DNA strands via electrostatic interactions were measured by chronocoulometry before and after hybridization. The increase of the charges of hexaamine-ruthenium III was observed upon hybridization of the probe with target DNA. Results indicate that this DNA biosensor could detect the femtomole (fM) concentration of the DNA target quantitatively in the range of 50 fM to 250 fM; the detection limit of this DNA biosensor was 5.6 fM (signal to noise = 3). This new biosensor exhibits excellent sensitivity and selectivity and has been used for an assay of polymerase chain reaction (PCR) with a satisfactory result.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.